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list who were tested positive for SARS-CoV-2. Severity of COVID-19 was categorised as follows: stage I,
mild symptoms; stage II, moderate to severe symptoms; stage III, critical symptoms; stage IV, death. We
compared the incidence rate (laboratory-confirmed cases of SARS-CoV-2), the hospital admission rate
(number of admissions of SARS-CoV-2-positive individuals), and the case fatality rate (number of deaths
of SARS-CoV-2-positive individuals) in our study population with the general Swiss population during the
study period, calculating age-adjusted standardised incidence ratios and standardised mortality ratios,
with 95% confidence intervals (CIs). RESULTS A total of 1439 patients were registered on the Swiss
national solid organ transplantation waiting list on 31 May 31 2020. Twenty-four (1.7%) waiting list
patients were reported to test positive for SARS-CoV-2 in the study period. The median age was 56 years
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patients aged >65 years with multiple comorbidities died in hospital from respiratory failure. Comparing
our study population with the general Swiss population, the age-adjusted standardised incidence ratio was
4.1 (95% CI 2.7–6.0). CONCLUSION The overall rate of SARS-CoV-2 infections in candidates awaiting
solid organ transplantation was four times higher than in the Swiss general population; however, the
frequency of testing likely played a role. Given the small sample size of affected patients, conclusions
have to be drawn cautiously and results need verification in larger cohorts. Keywords: COVID-19, organ
transplantation, SARS-CoV-2, waiting list
DOI: https://doi.org/10.4414/smw.2020.20451






The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives
4.0 International (CC BY-NC-ND 4.0) License.
Originally published at:
Benden, Christian; Haile, Sarah; Kruegel, Nathalie; Beyeler, Franziska; Aubert, John-David; Binet,
Isabelle; Golshayan, Dla; Hadaya, Karine; Mueller, Thomas; Parvex, Paloma; Immer, Franz (2020).




Original article | Published 31 December 2020 | doi:10.4414/smw.2020.20451
Cite this as: Swiss Med Wkly. 2020;150:w20451
SARS-CoV-2 / COVID-19 in patients on the Swiss
national transplant waiting list
Benden Christianab, Haile Sarah R.c, Kruegel Nathaliea, Beyeler Franziskaa, Aubert John-Davidd, Binet Isabellee, Golshayan
Délad, Hadaya Karinef, Mueller Thomas F.g, Parvex Palomaf, Immer Franz F.a
a Swisstransplant, Berne, Switzerland
b University of Zurich Faculty of Medicine, Zurich, Switzerland
c Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Switzerland
d Lausanne University Hospital, Lausanne, Switzerland
e Cantonal Hospital St Gallen, Switzerland
f Geneva University Hospitals, Geneva, Switzerland
g University Hospital Zurich, Switzerland
Summary
AIMS OF THE STUDY: The impact of coronavirus disease
2019 (COVID-19) on patients listed for solid organ trans-
plantation has not been systematically investigated to
date. Thus, we assessed occurrence and effects of infec-
tions with severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) on patients on the Swiss national waiting
list for solid organ transplantation.
METHODS: Patient data were retrospectively extracted
from the Swiss Organ Allocation System (SOAS). From 16
March to 31 May 2020, we included all patients listed for
solid organ transplantation on the Swiss national waiting
list who were tested positive for SARS-CoV-2. Severity of
COVID-19 was categorised as follows: stage I, mild symp-
toms; stage II, moderate to severe symptoms; stage III,
critical symptoms; stage IV, death. We compared the inci-
dence rate (laboratory-confirmed cases of SARS-CoV-2),
the hospital admission rate (number of admissions of
SARS-CoV-2-positive individuals), and the case fatality
rate (number of deaths of SARS-CoV-2-positive individu-
als) in our study population with the general Swiss pop-
ulation during the study period, calculating age-adjusted
standardised incidence ratios and standardised mortality
ratios, with 95% confidence intervals (CIs).
RESULTS: A total of 1439 patients were registered on the
Swiss national solid organ transplantation waiting list on
31 May 31 2020. Twenty-four (1.7%) waiting list patients
were reported to test positive for SARS-CoV-2 in the study
period. The median age was 56 years (interquartile range
45.3–65.8), and 14 (58%) were male. Of all patients test-
ed positive for SARS-CoV-2, two patients were asympto-
matic, 14 (58%) presented in COVID-19 stage I, 3 (13%)
in stage II, and 5 (21%) in stage III. Eight patients (33%)
were admitted to hospital, four (17%) required intensive
care, and three (13%) mechanical ventilation. Twenty-two
patients (92%) of all those infected recovered, but two
male patients aged >65 years with multiple comorbidities
died in hospital from respiratory failure. Comparing our
study population with the general Swiss population, the
age-adjusted standardised incidence ratio was 4.1 (95%
CI 2.7–6.0).
CONCLUSION: The overall rate of SARS-CoV-2 infec-
tions in candidates awaiting solid organ transplantation
was four times higher than in the Swiss general popula-
tion; however, the frequency of testing likely played a role.
Given the small sample size of affected patients, conclu-
sions have to be drawn cautiously and results need verifi-
cation in larger cohorts.
Keywords: COVID-19, organ transplantation, SARS-
CoV-2, waiting list
Introduction
At the end of 2019, a novel coronavirus, severe acute respi-
ratory syndrome coronavirus 2 (SARS-CoV-2), emerged in
the Chinese province of Hubei, causing a pandemic of un-
known extent [1, 2]. The disease caused by SARS-CoV-2
was named coronavirus disease 2019 (COVID-19) by the
World Health Organization and declared an internation-
al public health emergency on 30 January 2020 [2]. The
COVID-19 pandemic has an ongoing tremendous impact
across the world with major consequences in health care,
world economy, and social affairs. As vaccinations have
just commenced and effective therapy options are limit-
ed, the number of new cases and the death toll are con-
tinuously rising [2]. In Europe, Italy was the first country
severely hit by the pandemic [3]. On a daily basis, thou-
sands of northern Italian citizens cross the Italian-Swiss
border to the canton of Ticino, the southernmost canton
of Switzerland, to commute to work; thus, it was expect-
ed that Switzerland would face a similar healthcare cri-
sis as Italy. On 24 February 2020, the first SARS-CoV-2
positive individual was diagnosed in Switzerland (canton
of Ticino) according to Swiss Federal Office of Public
Health (FOPH) [4]. Initially, the impact of the pandemic
on healthcare systems in China and Italy emerged, in par-
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ticular, shortness of intensive care unit (ICU) capacity and
lack of hospital resources; in addition, there was primarily
scarce information on COVID-19 and its effect on organ
donation and solid organ transplantation [5].
Like Italy, where particularly Lombardy in the north of the
country was struck by the pandemic, the pandemic also
grew heterogeneously in Switzerland with its 8,700,000
citizens, affecting the various cantons differently. The
highest incidence of SARS-CoV-2 infection was recorded
in the French- and Italian-speaking Swiss cantons, with
>100 confirmed cases per 10,000 inhabitants in the canton
of Geneva and >90 confirmed cases per 10,000 inhabitants
in the canton of Ticino [6].
Early on in the pandemic, Loupy and coworkers published
data to quantify the impact of the COVID-19 pandemic on
organ donation and transplantation in France and the USA,
showing a clear association between the rise of COVID-19
infections and the fall in numbers of solid organ trans-
plantation [7]. There was an over 90% overall drop in de-
ceased organ transplant procedures since the start of the
pandemic in France and over 50% in the USA [7]. The de-
cline in transplant activities has consequences for the vul-
nerable population of patients with end-stage organ dis-
ease waiting for solid organ transplantation. Sharma and
colleagues from the UK showed that an estimated 1670
kidney transplant opportunities potentially were gone as
a result of the pandemic in the UK, leading to an almost
50% increase in patients awaiting kidney transplant based
on usual transplant figures [8]. The latter is very concern-
ing given the fact that patients on dialysis awaiting kidney
transplant are a vulnerable sub-group of patients, frequent-
ly with multiple comorbidities. A recent meta-analysis in-
cluding more than 70,000 patients from 21 studies revealed
that cardiovascular complications in particular are com-
mon in patients diagnosed with COVID-19, likely adding
to COVID-19-associated morbidity and mortality [9].
However, there is a paucity of data on SARS-CoV-2 infec-
tion and COVID-19 in patients with end-stage organ fail-
ure awaiting solid organ transplantation. A recent publica-
tion of (lately published) first experiences of SARS-CoV-2
in solid organ transplantation in Switzerland focused only
on patients post-transplant (after solid organ transplanta-
tion) using Swiss Transplant Cohort Study (STCS) data
[10]. The study by Tschopp et al. revealed that clinical
symptoms of COVID-19 in middle-aged solid organ trans-
plantation patients appeared comparable to the general
population, without higher complication rates detected
[10].
To our knowledge, SARS-CoV-2 infection rates and dis-
ease outcomes of COVID-19 in a well-defined group of
patients with end-stage organ failure listed for solid organ
transplantation have not been investigated to date. Thus,
we aimed to assess SARS-CoV-2 infection rates and
COVID-19 and its disease-related risks and outcomes in
patients on the Swiss national solid organ transplantation
waiting list. We hypothesised that the overall rate of
SARS-CoV-2 infections in solid organ transplantation can-
didates is probably comparable to that in the general pop-
ulation, but that the morbidity and mortality rate of
COVID-19 is likely to be raised.
Materials and methods
Study population
For the purpose of our study, patient data were retrospec-
tively extracted from the Swiss Organ Allocation System
(SOAS). During the study period from 16 March to 31
May 31 2020, we included all adult and paediatric patients
(<18 years of age) listed for solid organ transplantation on
the Swiss national waiting list who were tested positive for
SARS-CoV-2, mandatorily reported to Swisstransplant by
their transplant centre and subsequently paused until clin-
ical recovery and exclusion of ongoing SARS-CoV-2 in-
fection by a negative test result. However, there was no
nationwide policy on systematic serial testing for SARS-
CoV-2 of patients on the national solid organ transplanta-
tion waiting list throughout the entire study period. The pa-
tients’ follow-up terminated at the end of the observation
period on 31 May 2020.
We collected patients’ characteristics including sex, age,
transplant organ type, waiting list status (active vs inac-
tive), waiting list times, smoking status and comorbidities.
With regards to the circumstances at time of first diagnosis
of SARS-CoV-2 infection, we compiled data on laboratory
values, chest imaging, clinical course (hospital admission;
ICU admission; mechanical ventilation), COVID-19-asso-
ciated clinical complications, and clinical outcomes (full
recovery; recovered with sequelae; not yet recovered;
death). Severity of COVID-19 was subcategorised using
the criteria of Siddiqi and Mehra: stage I, mild symptoms
(e.g., dry cough, fatigue, headache); stage II, moderate to
severe symptoms (e.g., dyspnoea, hypoxia); stage III, crit-
ical symptoms (e.g., acute respiratory distress syndrome
[ARDS], cardiac failure); stage IV, death [11].
To accomplish our project, we used data collected by Swis-
stransplant and stored in the SOAS for quality control pur-
poses amongst others, as mandated by the Swiss Federal
Office of Public Health (FOPH). Our research was con-
ducted in accordance with the Helsinki Declaration as re-
vised in 2013.
Statistical analysis
Descriptive statistics were utilised to describe patients’ de-
mographics, COVID-19 stage and clinical outcome. Data
were summarised as n (%) or median (interquartile range,
IQR). We compared the incidence rate (laboratory-con-
firmed cases of SARS-CoV-2), the hospital admission rate
(number of admissions of SARS-CoV-2-positive individu-
als) and the case-fatality rate (number of deaths of SARS-
CoV-2-positive individuals) in our study population with
the general population of Switzerland (and the Principality
of Liechtenstein) during the study period, calculating age-
adjusted standardised incidence ratios (SIRs) and standard-
ised mortality ratios (SMRs), and 95% confidence inter-
vals (CIs) [12]. Publicly available data of the FOPH were
used [13–15].
Results
At the end of the study period on 31 May 2020, a total
of 1439 patients were registered on the Swiss national
solid organ transplantation waiting list in the SOAS. In
detail, 1027 (71%) of patients awaited kidney transplant,
211 (15%) awaited liver transplants, 91 (6%) heart trans-
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plants, 47 (3%) lung transplants, and 63 (4%) other trans-
plant types (pancreas, small bowel, and multi-organ trans-
plants). Only 1% of waiting list patients (n = 15) belonged
to the paediatric age group (<18 years of age). Of the total
1439 waiting list patients, 744 (52%) were actively list-
ed for transplant on 31 May 2020, 695 (48%) were tem-
porarily paused on the waiting list, most commonly in the
sub-group of patients awaiting kidney transplant (n = 520;
75%).
In the observation period from 16 March to 31 May 2020,
a total of 24 (1.7%) national waiting list patients (including
1 paediatric patient aged <18 years of age) were reported
to test positive for SARS-CoV-2 RNA; all these patients
were reported to Swisstransplant by the centre according
to Swiss national recommendations and subsequently tem-
porarily paused on the waiting list to monitor SARS-CoV-2
infection, clinical development and outcomes cases of
COVID-19. The median age of the SARS-CoV-2-infected
patients was 56 years (IQR 45.6–65.8), 10 patients (42%)
were 60 years of age or older, and more than half of pa-
tients were male (14; 58%). The vast majority of patients
awaited kidney transplant (n = 21; 88%), all of them on
renal replacement therapy, of the remaining three patients,
two awaited abdominal double organ transplantation, and
one patient lung transplant. With regards to the total num-
ber of patients on the waiting list according to primary in-
dication for solid organ transplantation, 2% of patients on
the kidney transplant waiting list and 2% of patients on
the lung transplantation waiting list were infected. At the
time of SARS-CoV-2 diagnosis, 14 (58%) were actively
listed for solid organ transplantation; this figure was sim-
ilar in the largest sub-group of patients awaiting kidney
transplant. Median waiting list time was 946 days (IQR
437–1449) for the whole group of 24 patients, and the me-
dian waiting list time for the sub-group of patients awaiting
kidney transplant was 982 days (IQR 582–1521). The me-
dian follow-up time of the study cohort was 53 days (IQR
34–58).
As to be expected in a group of patients awaiting pre-
dominantly kidney transplant, comorbidities were very fre-
quent. Eighty-one percent of kidney transplant waiting list
patients suffered from hypertension, and it was the most
common comorbidity also in the overall patient population
(n = 24, 79%) patients. The second most frequent comor-
bidity was obesity in 42% of the overall patient cohort and
43% in the sub-group of patients awaiting kidney trans-
plant. Further details on comorbidities are displayed in
table 1. Psychiatric or neurological complications associat-
ed with COVID-19 were not investigated routinely as part
of this study. One kidney transplant candidate aged >65
years was an active smoker; data on smoking status was
available in 23 (96%) patients.
Only two (8%) of the patients tested positive for SARS-
CoV-2 were asymptomatic. As shown in table 2, 14 (58%)
of the patients presented with COVID-19 stage I according
to Siddiqi and Mehra [11], 3 (13%) of patients stage II, and
5 (21%) with stage III. For further details see table 2.
Laboratory values were available for only some of the pa-
tients, as detailed in table 3. Further, seven (44%) of pa-
tients were leucopenic and two (18%) were lymphopenic.
The median C-reactive protein (CRP) value was mildly
raised (16 mg/l, IQR 2.0–155; normal range in adults <5
mg/l); 10 (71%) patients presented with a CRP value above
the normal range. The median procalcitonin level (avail-
able in 29% of patients) was moderately elevated (1.8 µg/
l, IQR 0.7–2.8); normal adult value <0.5 µg/l) with six
(86%) patients having an abnormal procalcitonin level.
Chest imaging (imaging technique not further specified)
was performed in 13 (54%) of the patient cohort and diag-
nosed as abnormal in 6 (46%) of those cases.
With regards to the clinical course following COVID-19
diagnosis, eight patients (33%) were admitted to the hospi-
tal, four (17%) were admitted to the ICU, and three (13%)
required mechanical ventilation (details for the sub-group
of kidney transplant candidates see table 3). The most fre-
quent complications among study patients were pneumo-
nia and ARDS, both occurred only in patients awaiting kid-
ney transplant (table 3).
Of the overall patient cohort, 22 (92%) recovered follow-
ing SARS-CoV-2 infection, and 100% of the non-kidney
transplant candidates recovered. Unfortunately, two pa-
tients (8%) died during the observation period due to
COVID-19. Both patients were male, aged >65 years,
awaiting kidney transplant, and each suffered from more
than three comorbidities. Both patients needed hospital and
Table 1: Comorbidities of patients on the waiting list tested positive for SARS-CoV-2.
Comorbidities All
n = 24 (100)
KTX
n = 21 (88)
Other
n = 3 (12)
Chronic heart failure 1 (4) 1 (5) –
Chronic lung disease 2 (8) 2 (10) –
Diabetes mellitus 4 (17) 3 (14) 1 (33)*
Hypertension 19 (79) 17 (81) 2 (67)
Obesity 10 (42) 9 (43) 1 (33)
Peripheral artery disease 4 (17) 4 (19) –
KTX = kidney transplantation. Data are presented as number (%). * n = 1 paediatric patient.
Table 2: COVID-19 stages at time of positive testing for SARS-CoV-2.
All
n = 24 (100)
KTX
n = 21 (88)
Other
n = 3 (12)
COVID-19 Stage I* 14 (58) 13 (62) 1 (33)
COVID-19 Stage II* 3 (13) 3 (14) –
COVID-19 Stage III* 5 (21) 5 (24) –
COVID-19 = coronavirus disease 2019; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; KTX = kidney transplantation. Data are presented as number (%). *
COVID-19 stages were adapted from Siddiqi and Mehra [10].
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ICU admission and mechanical ventilation as they devel-
oped pneumonia followed by ARDS. None of the study pa-
tients underwent transplantation during the study period.
In the comparison our study population with the general
population of Switzerland and the Principality of Liechten-
stein (8.74 million) [13, 14], there were a total of 30,924
laboratory-confirmed cases of SARS-CoV-2 in the study
period [15], resulting in a SIR of 4.1 (95% CI 2.7–6.0).
Further, a total of 3972 SARS-CoV-2 positive individuals
were admitted to hospital in Switzerland and the Principal-
ity of Liechtenstein in the study period [15], resulting in
an age-adjusted SIR for hospital admission of 10.5 (95%
CI 5.3–21.1). Of the 30,838 laboratory-confirmed cases of
SARS-CoV-2 in the general population, 1657 individuals
died due to COVID-19, resulting in an age-adjusted SMR
of 14.2 (95% CI 3.6–57.0).
Discussion
Our study investigating SARS-CoV2 infection rates and
COVID-19 outcomes in candidates on the national Swiss
waiting list for solid organ transplantation revealed that on-
ly a minority of <2% of a total of over 1400 registered
waiting list patients tested positive for SARS-CoV-2 be-
tween 16 March and 31 May 2020, 21 (88%) of those can-
didates for kidney transplant. Over half of patients (n =
14, 58%) presented with mild disease (COVID-19 stage
I), and 5 (21%) with advanced disease (COVID-19 stage
III). Yet overall post-COVID-19 outcome was favourable,
with 9 out of 10 patients recovering, 2 patients (8%) passed
away due to COVID-19-associated complications. In con-
trast, Boyarsky et al. from Baltimore, USA, revealed a
higher positive rate of diagnostic SARS-CoV-2 tests of
17% among 152 patients with end-stage renal disease [16].
The overall rate of SARS-CoV-2 infections in our study
population was four times higher than in the general pop-
ulation, although the frequency of testing likely plays a
role here. The SARS-CoV-2 positive transplant candidates
were significantly more often hospitalised. Furthermore,
our SARS-CoV-2-positive study patients died more often
from COVID-19 compared with the general Swiss popula-
tion.
To the authors’ knowledge, there is a lack of published
data regarding SARS-CoV-2 infection and COVID-19 in
patients on a solid organ transplantation waiting list during
the pandemic. Published literature to date reporting on the
COVID-19 pandemic and solid organ transplantation fo-
cusses primarily on the pandemic’s effect on organ dona-
tion itself and transplant activity, rather than on SARS-
CoV-2 infection rates and COVID-19 in candidates
awaiting solid organ transplantation. The COVID-19 pan-
demic struck Switzerland heterogeneously, with the high-
est incidence of SARS-CoV-2 infection recorded in the
French- and Italian speaking cantons neighbouring France
and Italy, respectively [6].
In our study, 88% of the patients tested positive for SARS-
CoV-2 during the study period were awaiting kidney trans-
plant requiring dialysis. As all of the kidney transplant
waiting list patients underwent renal replacement therapy,
the frequency of SARS-CoV-2 testing might play a role.
Furthermore, the two deaths in the study population oc-
curred in patients awaiting kidney transplant with multiple
comorbidities including hypertension and obesity. Hernán-
dez-Galdamez et al. from Mexico investigated the in-
creased risks of hospitalisation and death in patients with
COVID-19 and pre-existing noncommunicable diseases
[17]. The cross-sectional national study including more
than 210,000 confirmed COVID-10 cases officially report-
ed to the Mexican health authorities up to 27 June 2020
showed that almost 50% of patients with COVID-19 suf-
fered from a comorbidity, the most common being hyper-
tension in one out of five cases [17]. Chronic kidney dis-
ease raised the risk of death the most (odds ratio [OR]
2.31), followed by diabetes (OR 1.69), immunosuppres-
sion (OR 1.62), obesity (OR 1.42), hypertension (OR 1.24)
and chronic obstructive pulmonary disease (OR 1.20) [13].
Comorbidities augmenting ICU admission risk and intu-
bation risk were diabetes, immunosuppression and obesity
[17]. In our study population, hypertension and obesity
were the most frequent comorbidities, in 19 (79%) and
10 (42%) of patients, respectively. Further, four (17%) of
patients were diagnosed with diabetes. In comparison, all
of these are less common in the Swiss general popula-
tion; 17.6% of the general population in Switzerland suf-
fers with hypertension according to the Swiss Health Ob-
servatory in 2017; 11.3% of the Swiss general population
Table 3: COVID-19 clinical diagnostics and outcome.
Variables All
n = 24 (100)
KTX
n = 21 (88)
Other
n = 3 (12)
Laboratory values, median (IQR)
Leucocyte count (G/l), n = 16 5.0 (3.1–6.8)*
Lymphocyte count (G/l),n = 11 0.8 (0.4–1.7)*
CRP (mg/l), n = 14 16 (2.0–155)*
Procalcitonin (µg/l), n = 7 1.8 (0.7–2.8)*
Clinical course
Hospital admission 8 (33)* 7 (33) 1 (33)
ICU admission 4 (17) 4 (19) –
Mechanical ventilation 3 (13) 2 (15) –
Complications
ARDS 5 (21) 5 (24) –
Pneumonia 8 (33) 8 (38) –
Acute kidney injury – – –
Acute thromboembolic event 1 (4) 1 (5) –
ARDS = acute respiratory distress syndrome; COVID-19 = coronavirus disease 2019; CRP = C-reactive protein; ICU = intensive care unit; IQR = interquartile range; KTX = kidney
transplantation Data are presented as numbers (percent) unless indicated otherwise. * n = 1 paediatric patient
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was obese and 4% of the general population was affected
by diabetes in 2017 [18].
Alp Ikeler from Nashville, USA, highlighted in a recently
published editorial the higher SARS-CoV-2 transmission
risk among dialysis patients due to logistical issues of de-
livering kidney replacement therapy [19]. Patients with
end-stage renal disease on dialysis require regular (day
care) admissions to the dialysis unit, usually multiple times
per week, and patients are kept longer in proximity with
fellow patients also undergoing dialysis [19]. Therefore, it
is imperative to put the appropriate strategies in place to
prevent SARS-CoV-2 transmission in dialysis units [19].
To the authors’ knowledge, SARS-CoV-2 cross infection
at dialysis units in Switzerland was not reported during the
study period.
Another important aspect is the known older age of dial-
ysis patients with regards to COVID-19 [19]. Poletti et
al. investigated age-specific SARS-CoV-2 infection fatal-
ity ratio and associated risk factors during the COVID-19
pandemic in Italy [20]. Based on the analysis of more than
5000 close contacts of COVID-19 cases, the infection fa-
tality ratio was 0.5% for people <70 years of age and
10.5% for older people. Further, risk of death after SARS-
CoV-2 infection turned out to be 1.8-fold higher for males
[20]. In our study population, the only two fatalities were
over 65 years old and male. Compared with the general
population, our study population was older (42% of trans-
plant candidates were ≥60 years of age vs 25% in the gen-
eral population), and 58% of our study population were
male compared to 49% in the general population [13, 14].
In our study, laboratory values at COVID-19 diagnosis
were available in only a sub-group of study patients, owing
to its retrospective design. The limited data set revealed
a minimally reduced median lymphocyte count, a mildly
raised median CRP, and a moderately elevated median
procalcitonin level. A latest systematic review and meta-
analysis evaluating clinical data, including laboratory find-
ings, radiographic features and outcomes of >60,000 in-
dividuals diagnosed with COVID-19, demonstrated that
CRP was raised in over three quarters of cases and lym-
phopenia present in almost two thirds of cases [21].
In order to ensure ongoing organ donation, protect solid
organ transplantation candidates and maintain transplant
activity even during the pandemic, international societies
such as the Transplant Infectious Diseases Section (TID)
of the Transplantation Society (TTS) had already set up
consensus guidance on COVID-19 for transplant clinicians
early in the pandemic, but the recommendation provided
is almost completely based on international expert opinion
only, with a low level of evidence [22–25]. The guidance
documents are “work in progress” continuously updated on
the basis of newer evidence emerging as the international
expert community learns more about COVID-19 while the
pandemic continues to heavily impact on health systems
worldwide and cause fatalities. A group of experts from
Texas provides guidance on solid organ transplantation
candidates that were implemented in the TTS consensus
guidance document [22]. All transplant candidates with ac-
tive COVID-19 are prohibited from undergoing transplan-
tation. Transplant candidates are to be assessed clinical-
ly and screened, mostly by nasopharyngeal or deep throat
swabs, to rule out SARS-CoV-2 by polymerase chain-re-
action testing (PCR); local protocols vary depending on
the pandemic status of the area. During the pandemic in
Switzerland, there was no general screening programme
for all the patients on the national solid organ transplan-
tation waiting list, but a negative SARS-CoV-2 screening
test has been mandatory within 72 hours prior to organ al-
location for both the transplant candidates and the donor
in order to proceed with transplant. To date, no donor-
to-recipient SARS-CoV-2 transmission has occurred in
Switzerland (Franz F Immer, personal communication).
Passamonti et al. have recently published their experience
of solid organ transplantation in the COVID-19 pandemic,
evaluating the COVID-19 incidence and mortality in all
individuals undergoing solid organ transplantation during
the pandemic in the North Italy Transplant Programme
[26]. A total of 124 patients received solid organ transplan-
tations in the study period, 5 (4%) were diagnosed with
COVID-19 (mean of 13 days post-solid organ transplanta-
tion). Five patients died during the study period; however,
only one patient died from COVID-19 (COVID-19-associ-
ated mortality 0.8%) [26].
Strength and limitations
It is the strength of our study that it investigated for the
first time SARS-CoV-2 infection rates and COVID-19 out-
comes in patients awaiting solid organ transplantation na-
tionwide using a central data base. However, our study also
has limitations, inherent to its nature as a registry data base
study in a country with a current population of 8.7 million
without systematic screening of all waiting list patients
for SARS-CoV-2; thus, SARS-CoV-2 might be underdiag-
nosed, as patients with mild symptoms might not have had
timely testing. Further, as a registry data base study, accu-
racy of data entry depends on the centres, in particular the
extent of completeness of clinical data compiled at time of
first diagnosis of SARS-CoV-2 infection, potentially creat-
ing bias. On the other hand, as all patients on the kidney
transplant waiting list were on renal replacement therapy,
testing for SARS-CoV-2 probably occurred more frequent-
ly in these patients. Laboratory values, for example, have
to be interpreted carefully; no standardised laboratory pro-
tocol was used as real world data were collected, and our
sample size was small. Likewise, data on chest imaging
were not available for all patients, and if so, provided in-
formation only in the event of abnormal radiology. No
specifics were available for the most common radiograph-
ic signs. In addition, no data were accessible on potential
long-term sequelae of COVID-19 beyond the end of the
observation period on 31 May 2020. Owing to data protec-
tion issues, we were also unable to investigate the regional
impact of SARS-CoV-2 infection and COVID-19 on solid
organ transplantation candidates, knowing that Swiss can-
tons were heterogeneously hit by the pandemic. Data on
clinical stages of COVID in laboratory-confirmed cases of
SARS-CoV-2 in the general population were not publicly
available.
Conclusion
The overall rate of SARS-CoV-2 infections in candidates
awaiting solid organ transplantation was four times higher
than in the Swiss general population; however, frequency
of testing likely played a role. SARS-CoV-2-positive wait-
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ing list patients were hospitalised much more often and
more likely to die from COVID-19 compared with the gen-
eral population in Switzerland. Preventive strategies re-
main generally important in the ongoing pandemic. In the
future, vaccination should be given priority to population
groups determined at risk based on published evidence.
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